Featured News
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Digital Dialogue: Lupus Awareness Month
LUPUS FEATURES
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
LUPUS NEWS
Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data
The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients and study cohorts, especially those collected on different microarray...
Doctors and patients monitor Lupus with mobile app
CLICK TO VIEW ORIGINAL ARTICLE > by Josh Mandell A Charlottesville company is helping to lead a global scientific effort to better understand and treat lupus, an autoimmune disease sometimes called “the cruel mystery.” AMPEL Bio Solutions, a biomedical...
Trial of LuPRO mobile app predicts Lupus flares
CLICK TO VIEW ORIGINAL ARTICLE > BY KATIE O'CONNOR, Richmond Times-Dispatch In 50 years, only one treatment was approved by the U.S. Food and Drug Administration to treat lupus, an autoimmune disease in which a person’s immune system attacks their healthy organs...
Digital Dialogue: Lupus Awareness Month
For Lupus Awareness Month in May, NBC12 hosted a Digital Dialogue Tuesday night featuring advocates and specialists in the Lupus field, treatment, coping with the disease, finding a cure and new advancements being pioneered right here in Virginia.
Lupus: the right drug for the right person at the right time
On average, it takes nearly six years for people with Lupus to be diagnosed from the time they notice their first symptoms. May is Lupus Awareness month, and Dr. Amrie Grammer, co-founder of Ampel BioSolutions talks with Wendy about the state of Lupus treatments and...
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK TO READ THE ARTICLE > CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ -- AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. Revealed in the...
Alterations in Macrophage Activation May Signal a Lupus Flare
By Lara C. Pullen, PhD CLICK TO VIEW ARTICLE > Rheumatologists lack a definitive diagnostic tool to determine whether a patient has systemic lupus erythematous (SLE) and/or when a patient will experience a lupus flare. New data suggest myeloid cells in SLE patients...
The state of lupus treatments and what the future looks like.
Les Sinclair talks with Dr. Amrie Grammer about AMPEL BioSolutions, a Charlottesville Virginia company that has reengineered the gene-based technology they developed for lupus to COVID19.
Data mining could lead to therapy advances
Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.